Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

University of California, San Diego14 enrolled

Overview

The purpose of this study is to evaluate the effects of ranolazine, an FDA-approved medication for the treatment of angina, on heart function by using echocardiography.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Ranolazine Diastolic Heart Failure Tissue Doppler Ultrasound Echocardiography

Interventions

ranolazineDRUG

extended release 500 mg twice a day for two weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Moderate of severe diastolic dysfunction, E/Ea\>12 * Preserved systolic function * NYHA Class I-II Exclusion Criteria: * QTc \>450 msec at enrollment * Taking medications that prolong QT interval or are potent inhibitors of CYP3A * Significant coronary artery disease * Severe valvular disease * Hepatic disease * Severe kidney disease * Women of childbearing age * Prior serious ventricular arrhythmia

Locations (1)

UCSD Medical Center

San Diego, California, United States

Outcomes

Primary Outcomes

Change in E/Ea

Time frame: 2 weeks

Secondary Outcomes

changes in mitral inflow parameters (E, A, IVRT, DT)

Time frame: 2 weeks

Changes in tissue doppler parameters (Ea, Aa)

Time frame: 2 weeks

Changes in pulmonary venous inflow (S, D, a reversal)

Time frame: 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.